Jaeger, Martin G. http://orcid.org/0000-0002-7985-9744
Schwalb, Björn http://orcid.org/0000-0003-2987-2622
Mackowiak, Sebastian D.
Velychko, Taras http://orcid.org/0000-0003-4087-3730
Hanzl, Alexander
Imrichova, Hana http://orcid.org/0000-0003-0385-1823
Brand, Matthias
Agerer, Benedikt http://orcid.org/0000-0002-0044-8396
Chorn, Someth
Nabet, Behnam http://orcid.org/0000-0002-6738-4200
Ferguson, Fleur M. http://orcid.org/0000-0003-4091-7617
Müller, André C.
Bergthaler, Andreas http://orcid.org/0000-0003-0597-1976
Gray, Nathanael S. http://orcid.org/0000-0001-5354-7403
Bradner, James E. http://orcid.org/0000-0002-2718-4415
Bock, Christoph http://orcid.org/0000-0001-6091-3088
Hnisz, Denes http://orcid.org/0000-0002-6256-1693
Cramer, Patrick http://orcid.org/0000-0001-5454-7755
Winter, Georg E. http://orcid.org/0000-0001-6606-1437
Article History
Received: 2 December 2019
Accepted: 24 April 2020
First Online: 1 June 2020
Competing interests
: G.E.W., J.E.B. and B.N. are inventors on patent applications related to the dTAG system (WO/2017/024318, WO/2017/024319, WO/2018/148443, WO/2018/148440). The dTAG<sup>V</sup>-1 molecule is the subject of a patent application filed by Dana-Farber Cancer Institute. N.S.G. is a scientific founder, member of the scientific advisory board (SAB) and equity holder for C4 Therapeutics, Syros, Soltego, B2S, Gatekeeper and Petra Pharmaceuticals. The Gray laboratory receives or has received research funding from Novartis, Takeda, Astellas, Taiho, Janssen, Kinogen, Voroni, Her2llc, Deerfield and Sanofi. J.E.B. is now an executive and shareholder of Novartis and has been a founder and shareholder of SHAPE (acquired by Medivir), Acetylon (acquired by Celgene), Tensha (acquired by Roche), Syros, Regenacy and C4 Therapeutics.